Clinical trial
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
NCT00485069 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00485069 |
|---|---|
| Title | REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study |
| Official title | Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety - |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson Disease, Parkinson's Disease |
| Intervention type | Drug |
| Interventions | ROP, ROP+L-Dopa |
| Enrollment | 123 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 12, 2007 |
| Last update posted | Dec 15, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: